|
1
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chien Chang CR, Makhson A, DHaens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lièvre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grávalos C, Cassinello J, Fernández-Rañada
I and Holgado E: Role of tyrosine kinase inhibitors in the
treatment of advanced colorectal cancer. Clin Colorectal Cancer.
6:691–699. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pietrantonio F, Petrelli F, Coinu A, Di
Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi
I, Lonati V, et al: Predictive role of BRAF mutations in patients
with advanced colorectal cancer receiving cetuximab and
panitumumab: A meta-analysis. Eur J Cancer. 51:587–594. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schwartzberg LS, Rivera F, Karthaus M,
Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A
randomized, multicenter phase II study of panitumumab plus modified
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab
plus mFOLFOX6 in patients with previously untreated, unresectable,
wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol.
32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peeters M, Oliner KS, Price TJ, Cervantes
A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, et
al: Analysis of KRAS/NRAS mutations in a phase III study of
panitumumab with FOLFIRI compared with FOLFIRI alone as second-line
treatment for metastatic colorectal cancer. Clin Cancer Res.
21:5469–5479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meyerhardt JA and Fuchs CS: Epidermal
growth factor receptor inhibitors and colorectal cancer. Oncology
(Williston Park). 18:(Suppl 14). 35–38. 2004.PubMed/NCBI
|
|
9
|
Bokemeyer C, Van Cutsem E, Rougier P,
Ciardiello F, Heeger S, Schlichting M, Celik I and Köhne CH:
Addition of cetuximab to chemotherapy as first-line treatment for
KRAS wild-type metastatic colorectal cancer: Pooled analysis
of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer.
48:1466–1475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sung FL, Poon TC, Hui EP, Ma BB, Liong E,
To KF, Huang DP and Chan AT: Antitumor effect and enhancement of
cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma
cells. In Vivo. 19:237–245. 2005.PubMed/NCBI
|
|
11
|
Nakata E, Hunter N, Mason K, Fan Z, Ang KK
and Milas L: C225 antiepidermal growth factor receptor antibody
enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat
Oncol Biol Phys. 59:1163–1173. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Concannon CG, Gorman AM and Samali A: On
the role of Hsp27 in regulating apoptosis. Apoptosis. 8:61–70.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Andrieu C, Taieb D, Baylot V, Ettinger S,
Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, et
al: Heat shock protein 27 confers resistance to androgen ablation
and chemotherapy in prostate cancer cells through eIF4E. Oncogene.
29:1883–1896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song TF, Zhang ZF, Liu L, Yang T, Jiang J
and Li P: Small interfering RNA-mediated silencing of heat shock
protein 27 (HSP27) Increases chemosensitivity to paclitaxel by
increasing production of reactive oxygen species in human ovarian
cancer cells (HO8910). J Int Med Res. 37:1375–1388. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sarto C, Valsecchi C, Magni F, Tremolada
L, Arizzi C, Cordani N, Casellato S, Doro G, Favini P, Perego RA,
et al: Expression of heat shock protein 27 in human renal cell
carcinoma. Proteomics. 4:2252–2260. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO,
Welch WJ and McGuire WL: Response of human breast cancer cells to
heat shock and chemotherapeutic drugs. Cancer Res. 52:3648–3654.
1992.PubMed/NCBI
|
|
18
|
Vargas-Roig LM, Gago FE, Tello O, Aznar JC
and Ciocca DR: Heat shock protein expression and drug resistance in
breast cancer patients treated with induction chemotherapy. Int J
Cancer. 79:468–475. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsui Y, Hadaschik BA, Fazli L, Andersen
RJ, Gleave ME and So AI: Intravesical combination treatment with
antisense oligonucleotides targeting heat shock protein-27 and
HTI-286 as a novel strategy for high-grade bladder cancer. Mol
Cancer Ther. 8:2402–2411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayashi R, Ishii Y, Ochiai H, Matsunaga A,
Endo T, Hasegawa H and Kitagawa Y: Suppression of heat shock
protein 27 expression promotes 5-fluorouracil sensitivity in colon
cancer cells in a xenograft model. Oncol Rep. 28:1269–1274.
2012.PubMed/NCBI
|
|
21
|
Tsuruta M, Nishibori H, Hasegawa H, Ishii
Y, Endo T, Kubota T, Kitajima M and Kitagawa Y: Heat shock protein
27, a novel regulator of 5-fluorouracil resistance in colon cancer.
Oncol Rep. 20:1165–1172. 2008.PubMed/NCBI
|
|
22
|
Matsunaga A, Ishii Y, Tsuruta M,
Okabayashi K, Hasegawa H and Kitagawa Y: Inhibition of heat shock
protein 27 phosphorylation promotes sensitivity to 5-fluorouracil
in colorectal cancer cells. Oncol Lett. 8:2496–2500.
2014.PubMed/NCBI
|
|
23
|
Garrido C, Mehlen P, Fromentin A, Hammann
A, Assem M, Arrigo AP and Chauffert B: Inconstant association
between 27-kDa heat-shock protein (Hsp27) content and doxorubicin
resistance in human colon cancer cells. The doxorubicin-protecting
effect of Hsp27. Eur J Biochem. 237:653–659. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi DH, Ha JS, Lee WH, Song JK, Kim GY,
Park JH, Cha HJ, Lee BJ and Park JW: Heat shock protein 27 is
associated with irinotecan resistance in human colorectal cancer
cells. FEBS Lett. 581:1649–1656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang F, Zhang P, Shi C, Yang Y and Qin H:
Immunohistochemical detection of HSP27 and hnRNP K as prognostic
and predictive biomarkers for colorectal cancer. Med Oncol.
29:1780–1788. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Z, Zhi J, Peng X, Zhong X and Xu A:
Clinical significance of HSP27 expression in colorectal cancer. Mol
Med Rep. 3:953–958. 2010.PubMed/NCBI
|
|
27
|
Tweedle EM, Khattak I, Ang CW, Nedjadi T,
Jenkins R, Park BK, Kalirai H, Dodson A, Azadeh B, Terlizzo M, et
al: Low molecular weight heat shock protein HSP27 is a prognostic
indicator in rectal cancer but not colon cancer. Gut. 59:1501–1510.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bedel R, Thiery-Vuillemin A, Grandclement
C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X,
Ferrand C, Tiberghien P, et al: Novel role for STAT3 in
transcriptional regulation of NK immune cell targeting receptor
MICA on cancer cells. Cancer Res. 71:1615–1626. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of
STAT3 is a marker of poor prognosis in human colorectal cancer.
Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
|
|
30
|
Weber A, Borghouts C, Delis N, Mack L,
Brill B, Bernard AC, Coqueret O and Groner B: Inhibition of Stat3
by peptide aptamer rS3-PA enhances growth suppressive effects of
irinotecan on colorectal cancer cells. Horm Mol Biol Clin Investig.
10:273–279. 2012.PubMed/NCBI
|
|
31
|
Courapied S, Sellier H, de Carné Trécesson
S, Vigneron A, Bernard AC, Gamelin E, Barré B and Coqueret O: The
cdk5 kinase regulates the STAT3 transcription factor to prevent DNA
damage upon topoisomerase I inhibition. J Biol Chem.
285:26765–26778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morikawa T, Baba Y, Yamauchi M, Kuchiba A,
Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, et
al: STAT3 expression, molecular features, inflammation patterns,
and prognosis in a database of 724 colorectal cancers. Clin Cancer
Res. 17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song H, Ethier SP, Dziubinski ML and Lin
J: Stat3 modulates heat shock 27kDa protein expression in breast
epithelial cells. Biochem Biophys Res Commun. 314:143–150. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shigeta K, Hayashida T, Hoshino Y,
Okabayashi K, Endo T, Ishii Y, Hasegawa H and Kitagawa Y:
Expression of epidermal growth factor receptor detected by
cetuximab indicates its efficacy to inhibit in vitro and in vivo
proliferation of volorectal cancer cells. PLoS One. 8:e663022013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jhawer M, Goel S, Wilson AJ, Montagna C,
Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, et al:
PIK3CA mutation/PTEN expression status predicts response of colon
cancer cells to the epidermal growth factor receptor inhibitor
cetuximab. Cancer Res. 68:1953–1961. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Salazar R and Ciardiello F: Optimizing
Anti-EGFR therapy in colorectal cancer. Clin Cancer Res.
21:5415–5416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zaanan A, Okamoto K, Kawakami H, Khazaie
K, Huang S and Sinicrope FA: The mutant KRAS gene up-regulates
BCL-XL protein via STAT3 to confer apoptosis resistance that is
reversed by BIM protein induction and BCL-XL antagonism. J Biol
Chem. 290:23838–23849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Subramaniam A, Shanmugam MK, Perumal E, Li
F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, et al:
Potential role of signal transducer and activator of transcription
(STAT)3 signaling pathway in inflammation, survival, proliferation
and invasion of hepatocellular carcinoma. Biochim Biophys Acta.
1835:46–60. 2013.PubMed/NCBI
|
|
39
|
Stope MB, Weiss M, Preuss M, Streitbörger
A, Ritter CA, Zimmermann U, Walther R and Burchardt M: Immediate
and transient phosphorylation of the heat shock protein 27
initiates chemoresistance in prostate cancer cells. Oncol Rep.
32:2380–2386. 2014.PubMed/NCBI
|
|
40
|
Yang H, Yamazaki T, Pietrocola F, Zhou H,
Zitvogel L, Ma Y and Kroemer G: Improvement of immunogenic
chemotherapy by STAT3 inhibition. OncoImmunology. 5:e10780612015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pozzi C, Cuomo A, Spadoni I, Magni E,
Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, Zampino MG,
et al: The EGFR-specific antibody cetuximab combined with
chemotherapy triggers immunogenic cell death. Nat Med. 22:624–631.
2016. View Article : Google Scholar : PubMed/NCBI
|
